Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03784677 · ClinicalTrials.gov registry record · Phase 1
A Phase I Study of SOR-C13 in Patients With Advanced Solid Tumors
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 11
- Enrollment target
NCT03784677: Completed Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT03784677 is a Phase 1 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 11 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03784677, a Phase 1 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 11 participants
- Enrollment target
Study Summary
This phase I trial studies the side effects and best dose of SOR-C13 in treating patients with solid tumors that have spread to other places in the body (advanced) and does not respond to treatment. Drugs used in chemotherapy, such as SOR-C13, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
Interventions
- DRUG TRPV6 Calcium Channel Inhibitor SOR-C13
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2019-07-29 |
| Est. Completion | 2023-06-20 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03784677
The ClinicalTrials.gov registry entry for NCT03784677 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which TRPV6 Calcium Channel Inhibitor SOR-C13 is the first listed.
NCT03784677 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03784677 about?
NCT03784677 is a clinical study titled "A Phase I Study of SOR-C13 in Patients With Advanced Solid Tumors". This phase I trial studies the side effects and best dose of SOR-C13 in treating patients with solid tumors that have spread to other places in the body (advanced) and does not respond to treatment. Drugs used in chemotherapy, such as SOR-C13, work in different ways to stop the growth of tumor cells...
What is the current status of trial NCT03784677?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 11 participants. The study started on 2019-07-29. Estimated completion is 2023-06-20.
What interventions are being tested in trial NCT03784677?
The interventions under investigation include: TRPV6 Calcium Channel Inhibitor SOR-C13 (DRUG).
Who is sponsoring clinical trial NCT03784677?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.